How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,179 results for

Hepatotoxic Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults

, Department of Internal Medicine I, University Hospital 2 Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany 3 Department of Clinical Epidemiology 4 Department of Clinical Endocrinology and Metabolism, Leiden University Medical Centre, Leiden, the Netherlands 5 Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark 6 Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA (...) 7 Endocrine Oncology and Nuclear Medicine, Institut Gustave Roussy, Villejuif, France 8 INSERM UMR 1185, Faculté de Médecine, Le Kremlin-Bicêtre, Université Paris Sud, Paris, France 9 Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy 10 Department of Pathology, Erasmus MC University Medical Center, Rotterdam, the Netherlands 11 Department of Pathology, University Medical Center

Full Text available with Trip Pro

2018 European Society of Endocrinology

182. Alcoholic Liver Disease

and close monitoring Consider norepinephrine + albumin if progressive HRS-1 Volume expansion with albumin Renal insufficiency Pan-culture, Chest X-Ray Infection Perform doppler abdominal US and if indicated, MRI Rule out HCC/biliary obstruction/Budd-Chiari Mechanical obstruction Use of any potential hepatotoxic substance in the last 3 months Uncertain alcohol intake history Atypical presentation and/or laboratory tests(eg.AST or ALT>400) All negative Review detailed history of medication, supplements (...) ). Owing to various susceptibility factors, individuals with long-term heavy alcohol use remain at risk for advanced liver disease with alcoholic steatohepatitis (ASH), cirrhosis, and hepa- tocellular carcinoma (HCC) ( 3 ). Most patients with ALD present for medical care aft er they have developed jaundice or complica- tions of cirrhosis ( 4 ). Identifi cation of ALD in the primary-care setting at an early stage and subsequent behavioral interventions should thus be encouraged. Compared with the recent

2018 American College of Gastroenterology

183. BHIVA guidelines on the management of HIV in pregnancy and postpartum

of labour. Please also see section 9.1.3 for HIGH-RISK neonatal management. 2D 6.4.4 In preterm labour, if the infant is unlikely to be able to absorb oral medications consider the addition of double-dose tenofovir DF to the woman’s treatment described in recommendation 6.7.3 to further load the infant. 2C 6.4.5 Women presenting in labour/with spontaneous rupture of the membranes (SROM)/requiring delivery without a documented HIV result must be advised to have an urgent HIV test. A reactive/positive (...) be repeated at 2 and 4 weeks after commencing ART to detect evidence of hepatotoxicity or immune reconstitution inflammatory syndrome (IRIS) and then monitored regularly throughout pregnancy and postpartum. 1C 7.1.3 Because there is no evidence of any adverse effect on maternal or neonatal health if women become pregnant while taking ART dually active against HBV, treatment should be continued. 1C 7.1.4 Tenofovir DF and emtricitabine or lamivudine should form the backbone of an antiretroviral regimen

2019 British HIV Association

184. Non-alcoholic Fatty Liver Disease, Diagnosis and Management

) Because this guidance document is lengthy, to make it easier for the reader, a list of all guidance statements and recommendations are pro- videdinatabularformasSupportingTableS1. De?nitions Forde?ningNAFLD,theremustbe(1)evidence of hepatic steatosis (HS), either by imaging or histology, and (2) lack of secondary causes of hepatic fat accumu- lation such as signi?cant alcohol consumption, long- term use of a steatogenic medication, or monogenic hereditary disorders (Table 1). In the majority (...) . For de?ning “advanced” ?brosis, this guidance document will be referring speci?cally to stages 3 or 4, that is, bridging ?brosisorcirrhosis. TABLE 1. Common Causes of Secondary HS Macrovesicular steatosis - Excessive alcohol consumption - Hepatitis C (genotype 3) -WD - Lipodystrophy - Starvation - Parenteral nutrition - Abetalipoproteinemia - Medications (e.g., mipomersen, lomitapide, amiodarone, methotrexate, tamoxifen, corticosteroids) Microvesicular steatosis - Reye’s syndrome - Medications

2018 American Association for the Study of Liver Diseases

187. Anticoagulants in non-valvular atrial fibrillation

95 9.2.3 Patient selection 95 9.2.4 Definition of clinical variables and medications 97 9.2.5 Statistical analysis 100 9.3 RESULTS 101 9.3.1 Prescription of oral anticoagulants in general practice in the general population and validation of proxies for the CHA2DS2-VASc and CHADS2 scores (part 1) 101 4 Anticoagulants in non-valvular atrial fibrillation KCE Report 279 9.3.2 Trends in prescriptions of OACs in general practice in people with atrial fibrillation (part 2)107 9.4 CONCLUSIONS 125 9.4.1 (...) ) 79 Table 21 – Overview of Belgian studies 88 Table 22 – Total and monitoring costs: Belgian studies 88 Table 23 – Incremental outcomes: Belgian studies 89 Table 24 – Incremental Cost-effectiveness Ratios (ICERs): Belgian studies 90 Table 25 – Definition of oral anticoagulants, based on the ATC code 97 Table 26 – Definition of medications recorded (=2 prescriptions in a year) 97 Table 27 – Definition of variables used in CHA2DS2-Vasc and CHADS2 scores 98 Table 28 – Definition of clinical

2017 Belgian Health Care Knowledge Centre

188. Acute lymphoblastic leukemia

Acute lymphoblastic leukemia CLINICAL PRACTICE GUIDELINE LYHE-005 Version 1 Page 1 of 70 Acute Lymphoblastic Leukemia Effective Date: July, 2016 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment (...) assessment using either flow cytometry or PCR. 3. Treatment: 3.1. Eligible adults under age 60 with Ph/BCR-ABL negative ALL should be treated with a pediatric-based protocol. 3.1.1. In Alberta the standard regimen is the modified Dana Farber Cancer Institute (DFCI) protocol. 3.1.2. Patients with co-morbidities may be treated with a ‘less toxic’ regimen. 3.2. Medically fit adults above age 60 with Ph/BCR-ABL negative ALL should be treated with curative intent. CLINICAL PRACTICE GUIDELINE LYHE-005 Version

2016 CPG Infobase

189. Analgesia and Anesthesia for the Breastfeeding Mother

Analgesia and Anesthesia for the Breastfeeding Mother ABM Protocol ABM Clinical Protocol #15: Analgesia and Anesthesia for the Breastfeeding Mother, Revised 2017 Sarah Reece-Stremtan, 1 Matilde Campos, 2 Lauren Kokajko, 1 and The Academy of Breastfeeding Medicine A central goal of The Academy of Breastfeeding Medicine is the development of clinical protocols, free from commercial interest or in?uence, for managing common medical problems that may impact breastfeeding success. These protocols (...) serve only as guidelines for the care of breastfeeding mothers and infants and do not delineate an exclusive course of treatment or serve as standards of medical care. Variations in treatment may be appropriate according to the needs of an individual patient. Background T hereislittlerigorousinformationinthescienti?c literature about anesthesia or procedural sedation in breastfeeding mothers. Recommendations in this area typi- cally focus on pharmacologic properties of anesthetic agents, limited

2017 Academy of Breastfeeding Medicine

190. Guideline for the management of adults with Systemic Lupus Erythematosus

Article Navigation Close mobile search navigation Article navigation January 2018 Article Contents Article Navigation The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults Caroline Gordon Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham,Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust,Rheumatology Department, University (...) Hospitals Birmingham NHS Foundation Trust, Birmingham, Search for other works by this author on: Maame-Boatemaa Amissah-Arthur Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Search for other works by this author on: Mary Gayed Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham,Rheumatology Department, University Hospitals Birmingham NHS

Full Text available with Trip Pro

2017 British Society for Rheumatology

191. British Association of Dermatologists guidelines for the management of pemphigus vulgaris

in medical dermatology. One of the dermatologists is also an oral medi- cine specialist. The draft document was circulated to the BAD membership, the British Dermatological Nursing Group, the Primary Care Dermatological Society, the Pemphigus Vulgaris Network and PEM Friends (U.K.) for comments, which were actively considered by the GDG, and peer reviewed by the Clinical Standards Unit of the BAD (made up of the T&G Sub- committee) prior to publication. 3.0 Methodology This set of guidelines has been

2017 British Association of Dermatologists

192. Guidelines on the management of abnormal liver blood tests

), together with a full blood count if not already performed within the previous 12 months. (level 2b, grade B) ? Research Recommendation 1: Further evidence is required to establish the cost-effectiveness of case finding for non-alcoholic fatty liver disease (NAFLD) in high-risk groups before it can be recommended. (level 5, grade D) ? Recommendation 2: Abnormal liver blood test results should only be interpreted after review of the previous results, past medical history and current medical condition (...) is estimated at just under 10%. 40 Primary sclerosing cholangitis-inflamma- tory bowel disease is associated with increased complications relating to liver disease, as well as increased colorectal cancer risk. 41 Periodic monitoring of liver blood tests is therefore common practice, with a low clinical threshold for investiga- tion of cholestatic liver blood tests by MRI. In the absence of currently approved medical therapy ongoing efforts clinically table 2 Liver aetiology table for patients with non

2017 British Society of Gastroenterology

193. BSR guideline on the management of gout

by this author on: Kelsey M. Jordan 6Rheumatology, Brighton and Sussex University Hospitals NHS Trust, Brighton Search for other works by this author on: Christian D. Mallen 4Research Institute for Primary Care and Health Sciences, Keele University, Keele Search for other works by this author on: Thomas M. McDonald 7Medicines Monitoring Unit, Ninewells Hospital and Medical School, Dundee Search for other works by this author on: George Nuki 8Institute for Genetics and Molecular Medicine, University (...) and results of a systematic literature review. Seventeen clinical management questions ( ) were subsequently subjected to additional focused systematic literature searches after transposition into 20 questions in Population, Comparator, Outcome, Time format [ ]. T able 1 Principal clinical questions considered 1. In patients with acute gout, does the use of ice packs reduce pain? 2. In patients with acute gout, what medication should be used to manage acute attacks? 3. For patients on diuretic therapy

Full Text available with Trip Pro

2017 British Society for Rheumatology

194. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

of Contents ICER Staff/Consultants University of Washington School of Pharmacy Modeling Group* Jeffrey A. Linder, MD, MPH, FACP Associate Professor of Medicine Division of General Medicine and Primary Care Brigham and Women’s Hospital Harvard Medical School Steven D. Pearson, MD, MSc President Institute for Clinical and Economic Review Daniel A. Ollendorf, PhD Chief Scientific Officer Institute for Clinical and Economic Review Rick Chapman, PhD, MS Director of Health Economics Institute for Clinical (...) Return to Table of Contents About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. ICER receives funding from government grants, non-profit foundations, health plans, provider groups, and health industry manufacturers. For a complete list of funders, visit http://www.icer

2017 California Technology Assessment Forum

195. Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value-Based Price Benchmarks

Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value-Based Price Benchmarks Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value- Based Price Benchmarks Final Evidence Report and Meeting Summary November 1, 2016 Institute for Clinical and Economic Review ICER Staff University of Washington School of Pharmacy Modeling Group David Rind, MD, MSc Chief Medical Officer, Institute for Clinical and Economic Review Daniel (...) of the cost-effectiveness model, and the resulting ICER reports do not necessarily represent the views of the UW. DATE OF PUBLICATION: November 1, 2016 We would also like to thank Margaret Webb of ICER for her contributions to this report. About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes

2017 California Technology Assessment Forum

196. CRACKCast Episode 132 – HIV/AIDS

. “black box” warnings for lactic acidosis NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) (efavirenz and rilpivirine) can result in neurologic and psychiatric side effects. INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS) Eg Raltegravir insomnia and dizziness / depression / suicide PROTEASE INHIBITORS (PIS) Eg Darunavir insulin resistance, hyperglycemia, diabetes, hyperlipidemia, lipodystrophy, hepatotoxicity, bleeding in patients with hemophilia, and PR interval prolongation This post (...) Physician in Calgary (SHC/FMC) and in Sports Medicine. His interests are in endurance sports, exercise as medicine, and wilderness medical education. When he isn’t outdoors with his family, he's brewing a coffee or dreaming up an adventure….. Latest posts by Chris Lipp ( ) - July 2, 2018 - June 25, 2018 - June 21, 2018 Follow CRACKCast Schedule Mondays: CRACKCast Tuesdays: Medical Concepts Wednesdays: Opinion Thursdays: Throwbacks Fridays: National Interest Submit Content Join our community of educators

2017 CandiEM

197. Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder

and patients about the potentially serious risks associated with the use of Vivitrol, including severe injection-site reactions, sudden opioid withdrawal during treatment initiation, vulnerability to opioid overdose, and hepatotoxicity. 24 To prevent severe injection-site reactions, Vivitrol must not be given intravenously, subcutaneously, or into adipose (fat) tissue. Customized needles of two different lengths are provided with the medication. The proper needle, based on body build, should be selected (...) . Naltrexone is an opioid-receptor antagonist that blocks the euphoric effects of opioids. Unlike other treatments for opioid use disorder, including buprenorphine/naloxone and methadone, naltrexone is not associated with the development of tolerance and dependence, and lacks the potential for misuse and diversion. However, because the oral formulation requires a daily dosage, poor adherence to the medication has limited its efficacy for the prevention of relapse in patients with opioid use disorder

2017 CADTH - Issues in Emerging Health Technologies

198. Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder

and patients about the potentially serious risks associated with the use of Vivitrol, including severe injection-site reactions, sudden opioid withdrawal during treatment initiation, vulnerability to opioid overdose, and hepatotoxicity. 24 To prevent severe injection-site reactions, Vivitrol must not be given intravenously, subcutaneously, or into adipose (fat) tissue. Customized needles of two different lengths are provided with the medication. The proper needle, based on body build, should be selected (...) . Naltrexone is an opioid-receptor antagonist that blocks the euphoric effects of opioids. Unlike other treatments for opioid use disorder, including buprenorphine/naloxone and methadone, naltrexone is not associated with the development of tolerance and dependence, and lacks the potential for misuse and diversion. However, because the oral formulation requires a daily dosage, poor adherence to the medication has limited its efficacy for the prevention of relapse in patients with opioid use disorder

2017 CADTH - Issues in Emerging Health Technologies

199. BSR and BHPR Non-Biologic DMARD Guidelines

by this author on: Patrick Gordon 2Rheumatology Department, King’s College Hospital NHS Foundation Trust, London Search for other works by this author on: Dimitrios Christidis 5Rheumatology Department, Epsom and St Helier University Hospitals NHS Trust, Epsom Search for other works by this author on: Sarah Galloway 6South Brent Health Centre, South Brent, Devon Search for other works by this author on: Eranga Hayes 7North Street Medical Practice, Peterborough Search for other works by this author on: Andrew (...) Jeffries 8Rheumatology Department, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool Search for other works by this author on: Scott Mercer 9Department of Pharmacy, Guy’s and St Thomas’ Hospital NHS Foundation Trust, London Search for other works by this author on: Janice Mooney 10School of Health Sciences, University of East Anglia, Norwich, UK Search for other works by this author on: Sander van Leuven 11Rheumatology Department, Radboud University Medical Centre, Nijmegen, Netherlands

Full Text available with Trip Pro

2017 British Society for Rheumatology

200. Chronic Liver Disease

]. a Principal Author, Northwestern University, Chicago, Illinois. b Co-Author and Panel Chair, Johns Hopkins University School of Medicine, Baltimore, Maryland. c University of Arizona, Banner University Medical Center, Tucson, Arizona. d Baylor University Medical Center, Dallas, Texas; American Association for the Study of Liver Diseases. e New York University Medical Center, New York, New York. f University of Texas, MD Anderson Cancer Center, Houston, Texas. g University of Alabama Medical Center (...) for patients taking hepatotoxic drugs. The most commonly used types of US elastography for assessment of liver fibrosis are TE and ARFI. TE is predominantly performed with FibroScan (Echosens, Paris, France) and can be performed at point of care during a patient’s clinic visit without any additional equipment. TE was developed before ARFI and has been heavily studied and validated more than other elastography methods as a method of diagnosing liver fibrosis. TE has a sensitivity and specificity of 70

2017 American College of Radiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>